Texas Permanent School Fund Corp Lowers Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Texas Permanent School Fund Corp lowered its stake in Moderna, Inc. (NASDAQ:MRNAFree Report) by 0.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 68,422 shares of the company’s stock after selling 329 shares during the period. Texas Permanent School Fund Corp’s holdings in Moderna were worth $7,067,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in MRNA. Cim Investment Management Inc. lifted its position in Moderna by 4.2% during the first quarter. Cim Investment Management Inc. now owns 2,139 shares of the company’s stock valued at $329,000 after buying an additional 86 shares during the period. Cetera Advisor Networks LLC lifted its position in Moderna by 0.5% during the fourth quarter. Cetera Advisor Networks LLC now owns 17,195 shares of the company’s stock valued at $3,088,000 after buying an additional 87 shares during the period. PFG Investments LLC lifted its position in Moderna by 2.1% during the second quarter. PFG Investments LLC now owns 4,383 shares of the company’s stock valued at $533,000 after buying an additional 91 shares during the period. Ancora Advisors LLC lifted its position in Moderna by 41.2% during the first quarter. Ancora Advisors LLC now owns 329 shares of the company’s stock valued at $51,000 after buying an additional 96 shares during the period. Finally, Sunbelt Securities Inc. lifted its position in Moderna by 7.5% during the first quarter. Sunbelt Securities Inc. now owns 1,428 shares of the company’s stock valued at $211,000 after buying an additional 100 shares during the period. Institutional investors own 64.51% of the company’s stock.

Analyst Upgrades and Downgrades

MRNA has been the subject of several recent analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $125.00 price target on shares of Moderna in a research report on Friday, January 12th. The Goldman Sachs Group lowered their price target on Moderna from $269.00 to $231.00 and set a “buy” rating for the company in a research report on Friday, November 3rd. Oppenheimer raised Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price target for the company in a research report on Tuesday, January 2nd. HSBC raised Moderna from a “reduce” rating to a “hold” rating and lowered their price target for the stock from $89.00 to $69.00 in a research report on Friday, November 3rd. Finally, Canaccord Genuity Group started coverage on Moderna in a research report on Wednesday, November 29th. They issued a “hold” rating and a $82.00 price target for the company. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $123.96.

Get Our Latest Stock Analysis on MRNA

Insider Activity at Moderna

In other Moderna news, CFO James M. Mock sold 772 shares of the stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $109.75, for a total transaction of $84,727.00. Following the completion of the sale, the chief financial officer now directly owns 3,632 shares of the company’s stock, valued at approximately $398,612. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, CFO James M. Mock sold 772 shares of the stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $109.75, for a total transaction of $84,727.00. Following the completion of the transaction, the chief financial officer now directly owns 3,632 shares in the company, valued at approximately $398,612. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, President Stephen Hoge sold 45,000 shares of the stock in a transaction that occurred on Wednesday, December 27th. The shares were sold at an average price of $100.01, for a total value of $4,500,450.00. Following the transaction, the president now owns 1,531,063 shares of the company’s stock, valued at $153,121,610.63. The disclosure for this sale can be found here. In the last ninety days, insiders sold 106,899 shares of company stock worth $10,732,838. 15.70% of the stock is owned by company insiders.

Moderna Trading Down 6.7 %

Shares of NASDAQ:MRNA opened at $87.41 on Friday. The stock has a 50 day moving average of $96.62 and a 200 day moving average of $96.00. The company has a market cap of $33.33 billion, a PE ratio of -9.35 and a beta of 1.69. The company has a current ratio of 2.46, a quick ratio of 2.35 and a debt-to-equity ratio of 0.04. Moderna, Inc. has a 12-month low of $62.55 and a 12-month high of $177.37.

About Moderna

(Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

See Also

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.